Clinical and radiological response of BRAF inhibition and MEK inhibition in patients with brain metastases from BRAF-mutated melanoma.

摘要: Patients with brain metastases (BM) from melanoma have an overall survival (OS) of 2-6 months after whole-brain radiotherapy. Targeted therapy (TT) is effective treatment for BRAF-mutated metastatic melanoma. Moreover, recent studies indicate intracranial responses TT in patients BM. We analyzed 146 BM treated vemurafenib, dabrafenib, or dabrafenib+trametinib between 2010 and 2016. determined clinical radiological response, progression-free (PFS), OS. Median OS was 11.2 [n=30; 95% confidence interval (CI): 6.8-15.7], 8.8 dabrafenib alone (n=31; CI: 3.9-13.7), 5.7 vemurafenib (n=85; 4.6-6.8). A significantly longer observed the group than (hazard ratio death, 0.52; 0.30-0.89; P=0.02). PFS all 4.1 months. 5.8 (95% 3.2-8.5), 3.0-8.4) 3.6 3.5-3.8) (P=0.54). total 63 (43%) had symptomatic Intracranial disease control rate at 8 weeks these 65 versus 70% extracranially. Neurological symptoms improved 46% BM, whereas 21%, they remained stable. vemurafenib. Improvement neurological seen almost half TT.